Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236.

Antibody therapy of cancer.

Author information

1
Ludwig Institute for Cancer Research; University of Melbourne; and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australia. andrew.scott@ludwig.edu.au

Abstract

The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00829166 NCT01120184.

PMID:
22437872
DOI:
10.1038/nrc3236
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center